New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State
We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However, complex (MTBC) strains are still the leading cause of morbidity and mortality by a single infectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of the wo...
Uloženo v:
| Vydáno v: | Clinical microbiology reviews Ročník 31; číslo 1 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.01.2018
|
| Témata: | |
| ISSN: | 1098-6618, 1098-6618 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However,
complex (MTBC) strains are still the leading cause of morbidity and mortality by a single infectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of the world's population is estimated by the WHO to be infected with latent TB. During the last decade, several studies have aimed to define the characteristics of dormant bacteria in these latent infections. General features of the shift to a dormant state encompass several phenotypic changes that reduce metabolic activity. This low metabolic state is thought to increase the resistance of MTBC strains to host/environmental stresses, including antibiotic action. Once the stress ceases (e.g., interruption of treatment), dormant cells can reactivate and cause symptomatic disease again. Therefore, a proper understanding of dormancy could guide the rational development of new treatment regimens that target dormant cells, reducing later relapse. Here, we briefly summarize the latest data on the genetics involved in the regulation of dormancy and discuss new approaches to TB treatment. |
|---|---|
| AbstractList | We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However,
complex (MTBC) strains are still the leading cause of morbidity and mortality by a single infectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of the world's population is estimated by the WHO to be infected with latent TB. During the last decade, several studies have aimed to define the characteristics of dormant bacteria in these latent infections. General features of the shift to a dormant state encompass several phenotypic changes that reduce metabolic activity. This low metabolic state is thought to increase the resistance of MTBC strains to host/environmental stresses, including antibiotic action. Once the stress ceases (e.g., interruption of treatment), dormant cells can reactivate and cause symptomatic disease again. Therefore, a proper understanding of dormancy could guide the rational development of new treatment regimens that target dormant cells, reducing later relapse. Here, we briefly summarize the latest data on the genetics involved in the regulation of dormancy and discuss new approaches to TB treatment. We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However, Mycobacterium tuberculosis complex (MTBC) strains are still the leading cause of morbidity and mortality by a single infectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of the world's population is estimated by the WHO to be infected with latent TB. During the last decade, several studies have aimed to define the characteristics of dormant bacteria in these latent infections. General features of the shift to a dormant state encompass several phenotypic changes that reduce metabolic activity. This low metabolic state is thought to increase the resistance of MTBC strains to host/environmental stresses, including antibiotic action. Once the stress ceases (e.g., interruption of treatment), dormant cells can reactivate and cause symptomatic disease again. Therefore, a proper understanding of dormancy could guide the rational development of new treatment regimens that target dormant cells, reducing later relapse. Here, we briefly summarize the latest data on the genetics involved in the regulation of dormancy and discuss new approaches to TB treatment.We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However, Mycobacterium tuberculosis complex (MTBC) strains are still the leading cause of morbidity and mortality by a single infectious disease, with 9.6 million cases and 1.5 million deaths reported. One-third of the world's population is estimated by the WHO to be infected with latent TB. During the last decade, several studies have aimed to define the characteristics of dormant bacteria in these latent infections. General features of the shift to a dormant state encompass several phenotypic changes that reduce metabolic activity. This low metabolic state is thought to increase the resistance of MTBC strains to host/environmental stresses, including antibiotic action. Once the stress ceases (e.g., interruption of treatment), dormant cells can reactivate and cause symptomatic disease again. Therefore, a proper understanding of dormancy could guide the rational development of new treatment regimens that target dormant cells, reducing later relapse. Here, we briefly summarize the latest data on the genetics involved in the regulation of dormancy and discuss new approaches to TB treatment. |
| Author | Alffenaar, Jan-Willem C Niemann, Stefan Caño-Muñiz, Santiago Anthony, Richard |
| Author_xml | – sequence: 1 givenname: Santiago surname: Caño-Muñiz fullname: Caño-Muñiz, Santiago organization: University of Cambridge, Department of Genetics, Cambridge, United Kingdom – sequence: 2 givenname: Richard surname: Anthony fullname: Anthony, Richard organization: National Institute for Public Health and the Environment, National Mycobateria Reference Laboratory, Bilthoven, The Netherlands – sequence: 3 givenname: Stefan surname: Niemann fullname: Niemann, Stefan organization: German Center for Infection Research (DZIF), Partner Site Borstel, Borstel, Germany – sequence: 4 givenname: Jan-Willem C surname: Alffenaar fullname: Alffenaar, Jan-Willem C email: j.w.c.alffenaar@umcg.nl organization: University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands j.w.c.alffenaar@umcg.nl |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29187395$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUN1LwzAcDDJxH_rms-TRl84kTdvkccz5AZsDneBbSbNfWKRtapIi--8tOMGnO-6Og7spGrWuBYSuKZlTysTdcvM6J4TkJKHFGZpQIkWS51SM_vExmobwSQjlPBUXaMwkFUUqswn6eIFvvOg675Q-QMCq3ePdAbzqoI9W420XrWsDNs7jzVG7SukI3vYNjn0FXve1CzZg22KF751vVBvxW1QRLtG5UXWAqxPO0PvDard8Stbbx-flYp3oVPCYZBS01oSnGcnTAjLJKYhUMGOEYaoqDGFKCqMlVdzQQTSV0WkGRHIxOIzN0O1v7zDhq4cQy8YGDXWtWnB9KKkshmZWcDJEb07RvmpgX3beNsofy7832A8PrmMc |
| CitedBy_id | crossref_primary_10_1080_07391102_2020_1797534 crossref_primary_10_1016_j_tube_2020_101945 crossref_primary_10_1038_s41429_018_0068_5 crossref_primary_10_1080_14787210_2018_1536546 crossref_primary_10_1111_nyas_14300 crossref_primary_10_1186_s12879_024_09566_9 crossref_primary_10_3389_fimmu_2020_02006 crossref_primary_10_1007_s00253_019_09645_x crossref_primary_10_1111_febs_14734 crossref_primary_10_1016_j_cbpa_2019_10_007 crossref_primary_10_1371_journal_ppat_1010459 crossref_primary_10_1007_s00284_023_03491_x crossref_primary_10_1016_j_ejmech_2023_115125 crossref_primary_10_1097_QCO_0000000000000704 crossref_primary_10_3389_fimmu_2021_742370 crossref_primary_10_3389_fmicb_2021_642487 crossref_primary_10_1038_s41598_021_81223_6 crossref_primary_10_1099_jmm_0_002027 crossref_primary_10_1007_s00203_021_02474_5 crossref_primary_10_1155_2018_1514381 crossref_primary_10_1164_rccm_202103_0534OC crossref_primary_10_1111_jam_15677 crossref_primary_10_4081_monaldi_2024_2984 crossref_primary_10_3389_fimmu_2020_621148 crossref_primary_10_1007_s00253_020_10513_2 crossref_primary_10_3390_polym10030297 crossref_primary_10_1007_s11274_025_04374_y crossref_primary_10_1016_j_addr_2021_113948 crossref_primary_10_1080_09168451_2018_1451740 crossref_primary_10_1002_jcb_28891 crossref_primary_10_1016_j_bioorg_2018_12_038 crossref_primary_10_1093_jac_dky060 crossref_primary_10_3389_fmicb_2023_1149041 crossref_primary_10_1038_s41467_021_21748_6 crossref_primary_10_3389_fimmu_2020_594572 crossref_primary_10_1007_s00253_019_09771_6 crossref_primary_10_1186_s12879_021_06967_y crossref_primary_10_3389_fmicb_2018_01367 crossref_primary_10_1038_s41467_021_22833_6 |
| ContentType | Journal Article |
| Copyright | Copyright © 2017 American Society for Microbiology. |
| Copyright_xml | – notice: Copyright © 2017 American Society for Microbiology. |
| DBID | NPM 7X8 |
| DOI | 10.1128/CMR.00060-17 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1098-6618 |
| ExternalDocumentID | 29187395 |
| Genre | Journal Article Review |
| GroupedDBID | --- .GJ 0R~ 18M 29B 2WC 39C 4.4 53G 5GY 5VS 6J9 ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ KQ8 NEJ NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UCJ W2D W8F WH7 WHG WOQ ZGI 7X8 AAGFI |
| ID | FETCH-LOGICAL-c384t-51eccc04350637e5941e8382ff8f2ab7f02a98fc91a4f1f8ffbfc35e09482a922 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 61 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000423745600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-6618 |
| IngestDate | Fri Sep 05 10:40:12 EDT 2025 Tue Feb 25 01:06:50 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Mycobacterium tuberculosis dormancy latency toxin-antitoxin teixobactin pretomanid persistent bedaquiline lassomycin |
| Language | English |
| License | Copyright © 2017 American Society for Microbiology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c384t-51eccc04350637e5941e8382ff8f2ab7f02a98fc91a4f1f8ffbfc35e09482a922 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://cmr.asm.org/content/cmr/31/1/e00060-17.full.pdf |
| PMID | 29187395 |
| PQID | 1970632740 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1970632740 pubmed_primary_29187395 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical microbiology reviews |
| PublicationTitleAlternate | Clin Microbiol Rev |
| PublicationYear | 2018 |
| SSID | ssj0014438 |
| Score | 2.5023718 |
| SecondaryResourceType | review_article |
| Snippet | We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However,
complex (MTBC) strains are still the leading... We are far away from the days when tuberculosis (TB) accounted for 1 in 4 deaths during the 19th century. However, Mycobacterium tuberculosis complex (MTBC)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| Title | New Approaches and Therapeutic Options for Mycobacterium tuberculosis in a Dormant State |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29187395 https://www.proquest.com/docview/1970632740 |
| Volume | 31 |
| WOSCitedRecordID | wos000423745600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGA_qVLz4mK_5IoLXujbJ2uQkMh1eOodM6K2kaQIDbefaCvvv_dJ27OJB8NJDS6FNvscv3-uH0B3nWvtUWvYyMIEslYEjEqYdmgqhrIZRP6nJJoLxmEeRmLQBt6Itq1zZxNpQp7myMfK-JwLwpnCGch_mX45ljbLZ1ZZCYxN1KEAZK9VBtM4iMEabVjjBHfBDfFX4Tnh_GL7d18NInJaq7FdwWTuZ0cF_P-8Q7bfwEj828nCENnTWRTsN4eSyi3bDNpV-jCIwb_ixnSiuCyyzFE_XzVj4tal2wQBqcbhUoPb1WOfqE5dVoheq-siLWYFnGZb4qW49KHGNXE_Q--h5OnxxWpoFR1HOSmfgwTYqF3AT_EGgB4J5mlNOjOGGyCQwLpGCGyU8yYwHN01iFB1oOBhyeELIKdrK8kyfI6wESalJ7Ux8w3zmSSlo6kvBAsqo5m4P3a5WLwYxtrkJmem8KuL1-vXQWbMF8byZtxET4XGbT7z4w9uXaA8gDW-CJFeoY0CJ9TXaVt_lrFjc1PIB1_Ek_AH0iMRo |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+Approaches+and+Therapeutic+Options+for+Mycobacterium+tuberculosis+in+a+Dormant+State&rft.jtitle=Clinical+microbiology+reviews&rft.au=Ca%C3%B1o-Mu%C3%B1iz%2C+Santiago&rft.au=Anthony%2C+Richard&rft.au=Niemann%2C+Stefan&rft.au=Alffenaar%2C+Jan-Willem+C&rft.date=2018-01-01&rft.eissn=1098-6618&rft.volume=31&rft.issue=1&rft_id=info:doi/10.1128%2FCMR.00060-17&rft_id=info%3Apmid%2F29187395&rft_id=info%3Apmid%2F29187395&rft.externalDocID=29187395 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6618&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6618&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6618&client=summon |